

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

UWB1.289

RRID:CVCL_B079

Type: Cell Line

Proper Citation

RRID:CVCL_B079

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B079

Proper Citation: RRID:CVCL_B079

Description: Cell line UWB1.289 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: BRCA1 syndrome

Defining Citation: [PMID:17259345](#), [PMID:25230021](#), [PMID:27397505](#), [PMID:29242379](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: UWB1.289

Synonyms: UWB1-289, UWB1289

Cross References: BTO:BTO_0006253, ArrayExpress:E-MTAB-3610, ATCC:CRL-2945, BioGRID_ORCS_Cell_line:1041, BioSample:SAMN03471702, cancercellines:CVCL_B079, Cell_Model_Passport:SIDM00815, Cosmic-CLP:1480374, DepMap:ACH-001418, EGA:EGAS00001000978, GDSC:1480374, GEO:GSM711714, GEO:GSM1291155, GEO:GSM1670568, Lonza:1665, Pharmacodb:UWB1_289_1650_2019, PRIDE:PXD006939, PRIDE:PXD030304, Wikidata:Q54992390

ID: CVCL_B079

Record Creation Time: 20220427T221706+0000

Record Last Update: 20260816T000121+0000

Ratings and Alerts

No rating or validation information has been found for UWB1.289.

No alerts have been found for UWB1.289.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science advances, 12(16), eaeb0855.

Vo N, et al. (2026) Detection of nuclear STING in cultured human cells and in the normal and cancer tissues. iScience, 29(5), 115711.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Lee H, et al. (2025) Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer. FEBS open bio.

Bashtanova U, et al. (2025) The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose. FEBS letters, 599(24), 3618.

Bedia JS, et al. (2025) Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models. Cell reports. Medicine, 6(9), 102295.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. Scientific reports, 15(1), 36766.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. *Cell reports. Medicine*, 5(2), 101376.

Nair JR, et al. (2024) Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. *iScience*, 27(12), 111283.

Rutkowska A, et al. (2024) Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation. *Cancer research communications*, 4(9), 2427.

McMellen A, et al. (2023) ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. *Molecular cancer research : MCR*, 21(1), 3.

Quintela M, et al. (2023) In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. *British journal of cancer*, 129(1), 163.

Silva R, et al. (2023) Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer. *International journal of cancer*, 153(1), 120.

Planas-Paz L, et al. (2023) Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. *EMBO molecular medicine*, 15(4), e16863.

Quintela M, et al. (2023) Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. *Clinical epigenetics*, 15(1), 63.

Li Y, et al. (2023) PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. *Cell reports. Medicine*, 4(12), 101326.

Jiang J, et al. (2022) Systematic illumination of druggable genes in cancer genomes. *Cell reports*, 38(8), 110400.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. *Molecular cancer therapeutics*, 21(4), 647.